Group 1 - H.C. Wainwright raised the price target on Palvella Therapeutics (PVLA) to $255 from $200 while maintaining a Buy rating on the shares [1] - The Phase 3 SELVA data showed a statistically significant 2.13-point mean change in the mLM-IGA primary endpoint, which is considered a "clear and decisive win" by the analyst [1] - The efficacy demonstrated in the SELVA trial is expected to lead to strong and continued uptake among patients if the treatment is approved [1]